BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 3, 2019
View Archived Issues
Re-turning turncoat macrophages
Read More
Drug takes aim at TB enzyme and its backup
Read More
Prenatal treatment improves cystic fibrosis
Read More
Patient enrollment underway in phase I study of AGEN-1181
Read More
FDA approves IND application for Incysus' gamma-delta T-cell therapy
Read More
Sangamo and Pfizer announce phase I/II interim data for SB-525 gene therapy
Read More
Tesamorelin leads to significant reductions in liver fat in HIV patients with NAFLD
Read More
New Alzheimer's disease model differentiates the role of C99 from beta-amyloid
Read More
Fish slime helps turn the tide against antibiotic resistance
Read More
Novel series of reversible USP7 inhibitors as oncolytic drugs presented
Read More
Decreased intraocular inflammation observed in MAPLE wet AMD study of abicipar
Read More
Monoclonal antibody against CLDN18.2 shows development potential for gastric cancer
Read More
Bispecific molecule PRS-342 shows robust in vitro and in vivo antitumoral effects
Read More
eFFECTOR Therapeutics candidate targets RNA helicase eIF4A for cancer
Read More
Dragonfly Therapeutics patents NKG2D-binding proteins for cancer
Read More
Stoke Therapeutics divulges new antisense oligomers
Read More
Alector initiates first-in-human study of AL-003 for Alzheimer's disease
Read More
Altor BioScience identifies new fusion proteins for treatment of cancer
Read More
FDA clears Cellectis to begin phase I trial of UCARTCS1 in multiple myeloma
Read More
Aldeyra initiates phase III trial of reproxalap in dry eye disease
Read More
Mologen synthesizes new TLR9 agonists
Read More
Phase I data reported for shERPA agent TTC-352
Read More
ProQR Therapeutics discloses new HTT-targeting antisense oligonucleotides
Read More
New phase Ib/IIa trial studies RTB-101 for Parkinson's disease
Read More
Dermelix partners with EspeRare on DMX-101 for X-linked hypohidrotic ectodermal dysplasia
Read More